Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR8526722

— · cohortMD2

eb8867c8-75ae-5ae0-b0e9-c1224104ae7b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
  • IL6_JAK_STAT3_SIGNALING+0.620
  • ALLOGRAFT_REJECTION+0.580
  • INFLAMMATORY_RESPONSE+0.580
  • TNFA_SIGNALING_VIA_NFKB+0.580
  • INTERFERON_GAMMA_RESPONSE+0.570
  • COMPLEMENT+0.560
  • HYPOXIA+0.510
  • INTERFERON_ALPHA_RESPONSE+0.480
  • COAGULATION+0.450

Top 10 suppressed

  • MYC_TARGETS_V2-0.690
  • MYC_TARGETS_V1-0.600
  • E2F_TARGETS-0.580
  • G2M_CHECKPOINT-0.520
  • OXIDATIVE_PHOSPHORYLATION-0.420
  • DNA_REPAIR-0.310
  • UNFOLDED_PROTEIN_RESPONSE-0.220
  • SPERMATOGENESIS-0.180
  • ESTROGEN_RESPONSE_LATE-0.130
  • WNT_BETA_CATENIN_SIGNALING-0.130

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR5088860
melanoma-umap@29
——0.931
2SRR22247245
lung-landscapes@6
—cohortMD20.931
3SRR8518191
breast-umap@18
—D0.928
4BS_Z0AVVB1V
brain-umap@2
pilocytic astrocytoma—0.925
5TCGA-22-4596-01A-01R-1201-07
lung-landscapes@6
—cohortA10.918
6SRR5088825
melanoma-umap@29
——0.918
7SRR5088910
melanoma-umap@29
——0.916
8TCGA-AO-A03U-01B-21R-A10J-07
breast-umap@18
—D0.915
9BS_W3R88RFP
brain-umap@2
pilocytic astrocytoma—0.915
10BS_D3YBV7KB
brain-umap@2
low-grade glioma—0.915

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.640Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.620Inavolisib— uncovered
ALLOGRAFT_REJECTION0.580Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.580Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.580Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.570Idelalisib— uncovered
COMPLEMENT0.560Inavolisib— uncovered
HYPOXIA0.510Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.480Inavolisib— uncovered
COAGULATION0.450Binimetinib— uncovered
KRAS_SIGNALING_UP0.420Inavolisib— uncovered
IL2_STAT5_SIGNALING0.400Idelalisib— uncovered
APOPTOSIS0.390Idelalisib— uncovered
TGF_BETA_SIGNALING0.330Inavolisib— uncovered
ANGIOGENESIS0.310Remibrutinib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
APICAL_JUNCTION0.290Inavolisib— uncovered
PROTEIN_SECRETION0.280Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.280Inavolisib— uncovered
UV_RESPONSE_DN0.260Inavolisib— uncovered